Skip to search form
Skip to main content
>
Semantic Scholar
Semantic Scholar's Logo
Search
Sign In
Create Free Account
You are currently offline. Some features of the site may not work correctly.
everolimus 5 MG Tablet for Oral Suspension [Afinitor]
Known as:
Afinitor Disperz 5 MG Tablet for Oral Suspension
, EVEROLIMUS 5 mg ORAL TABLET, FOR SUSPENSION [Afinitor Disperz]
National Institutes of Health
Create Alert
Related topics
Related topics
9 relations
Butylated Hydroxytoluene
Crospovidone
Lactose Monohydrate
Magnesium stearate
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
R. Mújica-Mota
,
J. Varley-Campbell
,
+11 authors
M. Hoyle
Health technology assessment
2018
Corpus ID: 52194429
BACKGROUND Neuroendocrine tumours (NETs) are a group of heterogeneous cancers that develop in cells in the diffuse neuroendocrine…
Expand
2016
2016
Neue Therapieoptionen bei Neuroendokrinen Tumoren des Gastrointestinaltraktes
R. Lipp
,
P. Kump
2016
Corpus ID: 59454912
Recent therapy options of gastro- intestinal neuroendocrine tumours. Neuroen- docrine tumors (NET) of gastroenteropancreatic (GEP…
Expand
2016
2016
Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells
Asona Lui
,
J. New
,
Joshua Ogony
,
S. Thomas
,
J. Lewis-Wambi
BMC Cancer
2016
Corpus ID: 1027379
BackgroundmTOR inhibition of aromatase inhibitor (AI)-resistant breast cancer is currently under evaluation in the clinic…
Expand
2015
2015
In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response
S. Hurvitz
,
O. Kalous
,
+9 authors
D. Slamon
Breast Cancer Research and Treatment
2015
Corpus ID: 70797
Everolimus (RAD001, Afinitor®) is an oral, selective mTOR inhibitor recently approved by the US-FDA in combination with…
Expand
Review
2013
Review
2013
Everolimus in Combination with Exemestane: A Review of its Use in the Treatment of Patients with Postmenopausal Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Sohita Dhillon
Drugs
2013
Corpus ID: 3100316
Oral everolimus (Afinitor®) in combination with exemestane is indicated for the treatment of hormone receptor-positive, human…
Expand
2012
2012
FDA Approves Everolimus (Afinitor Disperz) for Rare Pediatric Brain Tumor
Ian Ingram
2012
Corpus ID: 150027658
The FDA approved a dissolvable form of everolimus (Afinitor Disperz) for the treatment of children with subependymal giant cell…
Expand
2012
2012
Everolimus (Afinitor® or Votubia®) in combination with exemestane in postmenopausal women with oestrogen receptor positive, HER2-negative locally advanced or metastatic breast cancer who are…
K. Jeitler
,
T. Semlitsch
2012
Corpus ID: 68235303
In Austria, about 24% of women with initially diagnosed breast cancer (BC) have locally advanced and about 5% have metastatic…
Expand
Review
2012
Review
2012
Pancreatic neuroendocrine neoplasms.
D. Hörsch
,
T. Bert
,
+5 authors
R. Baum
Minerva gastroenterologica e dietologica
2012
Corpus ID: 24180884
Pancreatic neuroendocrine tumors originate from the diffuse neuroendocrine system in the pancreatic region. These tumors exhibit…
Expand
2009
2009
Everolimus (Afinitor®), Trastuzumab (H), and Paclitaxel (P) or Vinorelbine (V) in the Treatment of HER-2+ Metastatic Breast Cancer (MBC) Patients (Pts) Pre-Treated with Lapatinib-Containing Therapy…
F. Cardoso
,
V. Diéras
,
+8 authors
L. Gianni
2009
Corpus ID: 71568351
Introduction: The re-introduction of H-based therapy after progression on a lapatinib-containing regimen has not yet been…
Expand
2009
2009
Everolimus (Afinitor®) for advanced/metastatic kidney cancer
A. Nachtnebel
2009
Corpus ID: 68182187
The purpose of this report was to evaluate efficacy and safety of second-line therapy with everolimus, an mTOR inhibitor, for the…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE